Literature DB >> 1323022

gyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase.

A Contreras1, A Maxwell.   

Abstract

Coumarins are inhibitors of the ATP hydrolysis and DNA supercoiling reactions catalysed by DNA gyrase. Their target is the B subunit of gyrase (GyrB), encoded by the gyrB gene. The exact mode and site of action of the drugs is unknown. We have identified four mutations conferring coumarin resistance to Escherichia coli: Arg-136 to Cys, His or Ser and Gly-164 to Val. In vitro, the ATPase and supercoiling activities of the mutant GyrB proteins are reduced relative to the wild-type enzyme and show resistance to the coumarin antibiotics. Significant differences in the susceptibility of mutant GyrB proteins to inhibition by either chlorobiocin and novobiocin or coumermycin have been found, suggesting wider contacts between coumermycin and GyrB. We discuss the significance of Arg-136 and Gly-164 in relation to the notion that coumarin drugs act as competitive inhibitors of the ATPase reaction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323022     DOI: 10.1111/j.1365-2958.1992.tb00886.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  48 in total

1.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  tRNA synthetase mutants of Escherichia coli K-12 are resistant to the gyrase inhibitor novobiocin.

Authors:  M Jovanovic; M Lilic; R Janjusevic; G Jovanovic; D J Savic; J Milija
Journal:  J Bacteriol       Date:  1999-05       Impact factor: 3.490

3.  Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.

Authors:  Christine D Hardy; Nicholas R Cozzarelli
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

4.  Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.

Authors:  Steven Bellon; Jonathan D Parsons; Yunyi Wei; Koto Hayakawa; Lora L Swenson; Paul S Charifson; Judith A Lippke; Robert Aldape; Christian H Gross
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  Characterization of the DNA gyrase from the thermoacidophilic archaeon Thermoplasma acidophilum.

Authors:  Kan Yamashiro; Akihiko Yamagishi
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

6.  Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.

Authors:  Katherine A Hurley; Thiago M A Santos; Molly R Fensterwald; Madhusudan Rajendran; Jared T Moore; Edward I Balmond; Brice J Blahnik; Katherine C Faulkner; Marie H Foss; Victoria A Heinrich; Matthew G Lammers; Lucas C Moore; Gregory D Reynolds; Galen P Shearn-Nance; Brian A Stearns; Zi W Yao; Jared T Shaw; Douglas B Weibel
Journal:  Medchemcomm       Date:  2017-02-27       Impact factor: 3.597

7.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  gyrB mutations in coumermycin A1-resistant Borrelia burgdorferi.

Authors:  D S Samuels; R T Marconi; W M Huang; C F Garon
Journal:  J Bacteriol       Date:  1994-05       Impact factor: 3.490

Review 9.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Biological characterization of cyclothialidine, a new DNA gyrase inhibitor.

Authors:  N Nakada; H Shimada; T Hirata; Y Aoki; T Kamiyama; J Watanabe; M Arisawa
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.